Edition:
United States

Neurocrine Biosciences Inc (NBIX.O)

NBIX.O on Nasdaq

72.28USD
17 Nov 2017
Change (% chg)

$-0.02 (-0.03%)
Prev Close
$72.30
Open
$70.95
Day's High
$72.48
Day's Low
$70.56
Volume
866,071
Avg. Vol
919,467
52-wk High
$75.98
52-wk Low
$37.35

Latest Key Developments (Source: Significant Developments)

Neurocrine Biosciences reports Q3 loss per share $0.13
Wednesday, 1 Nov 2017 04:01pm EDT 

Nov 1 (Reuters) - Neurocrine Biosciences Inc :Neurocrine Biosciences reports third quarter 2017 results.Q3 loss per share $0.13.Q3 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S.Says net product sales of $45.8 million for three months ended September 30, 2017​.  Full Article

Abbvie receives U.S. FDA priority review for investigational Oral Treatment Elagolix
Friday, 27 Oct 2017 07:00am EDT 

Oct 27 (Reuters) - Abbvie Inc :Abbvie receives U.S. FDA priority review for Investigational Oral Treatment Elagolix for the management of Endometriosis with associated pain.Abbvie inc - ‍expects PDUFA date for FDA to complete its review will be in Q2 2018​.  Full Article

Neurocrine initiates Phase IIb clinical study of Ingrezza
Wednesday, 25 Oct 2017 04:01pm EDT 

Oct 25 (Reuters) - Neurocrine Biosciences Inc :Neurocrine initiates phase IIb clinical study of once-daily Ingrezza in children and adolescents with Tourette syndrome.Neurocrine Biosciences Inc - ‍top-line data from study is expected in late 2018​.  Full Article

Neurocrine granted FDA orphan drug designation for Valbenazine
Monday, 23 Oct 2017 04:57pm EDT 

Oct 23 (Reuters) - Neurocrine Biosciences Inc :Neurocrine granted FDA orphan drug designation for valbenazine for the treatment of pediatric patients with Tourette syndrome.  Full Article

Neurocrine Biosciences says David-Alexander Gros resigns as COO and interim CFO of co
Thursday, 19 Oct 2017 05:52pm EDT 

Oct 20 (Reuters) - Neurocrine Biosciences Inc :Neurocrine Biosciences Inc - ‍on Oct. 18, David-Alexander C. Gros resigned as president, COO and interim CFO of co, effective as of Oct. 19 - SEC filing.Neurocrine Biosciences Inc - ‍in connection with resignation of Gros, effective Oct. 19, Kevin C. Gorman​ was appointed as company's interim CFO.  Full Article

Neurocrine announces FDA approval of 80 mg Ingrezza
Thursday, 5 Oct 2017 07:00am EDT 

Oct 5 (Reuters) - Neurocrine Biosciences Inc : :Neurocrine announces FDA approval of 80 mg Ingrezza® (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD).Says ‍80 mg capsule of Ingrezza will be available for patients within two weeks through a select pharmacy network​.  Full Article

Perceptive Advisors reports 5.3 pct passive stake in Neurocrine Biosciences
Friday, 8 Sep 2017 09:00am EDT 

Sept 8 (Reuters) - Neurocrine Biosciences Inc :Perceptive Advisors LLC reports 5.3 percent passive stake in Neurocrine Biosciences Inc as of September 6, 2017 - SEC filing‍​.  Full Article

Neurocrine Biosciences Q2 loss per share $0.68
Thursday, 3 Aug 2017 04:01pm EDT 

Aug 3 (Reuters) - Neurocrine Biosciences Inc :Neurocrine Biosciences reports second quarter 2017 results.Q2 loss per share $0.68.Q2 earnings per share view $-0.66 -- Thomson Reuters I/B/E/S.Qtrly ‍total revenues of $6.3 million.  Full Article

Neurocrine Biosciences says on July 10, co, Patheon UK Ltd entered into amended, restated product agreement to product agreement entered into on Nov 28
Wednesday, 12 Jul 2017 05:14pm EDT 

July 12 (Reuters) - Neurocrine Biosciences Inc :Neurocrine Biosciences - On July 10, co, Patheon UK Ltd entered into amended, restated product agreement to product agreement entered into on Nov 28, 2016.Neurocrine Biosciences - Amended and restated product agreement finalizes batch sizes and corresponding pricing for 80 mg Ingrezza capsules - SEC Filing.Neurocrine Biosciences - Amended and restated product agreement provides for clarification of testing requirements related to manufacture of Ingrezza.  Full Article

Neurocrine Biosciences says PDUFA goal date is Oct. 14 for Ingrezza 80 mg capsules
Wednesday, 5 Jul 2017 07:22am EDT 

July 5 (Reuters) - Neurocrine Biosciences Inc :Neurocrine Biosciences Inc - has been advised that PDUFA goal date is october 14, 2017 for Ingrezza 80 mg capsules - sec filing.  Full Article